← Leaderboards
Alexander E Davies
Ohio State University
$598,565
Attributed
$598,565
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $119.7K · FY2021–25$200K$150K$100K$50K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$598,565 · 1
By mechanism
K01$598,565 · 1
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Lawrence S Kirschner$10,043,463
- Sydney Fobare$195,812
- Elliott D Crouser$4,838,276
- Martin F Sarter$13,437,306
- Stacey Lea Fossey$189,121
Others in their field
Other Emerging Leaders on “Abcc1 Gene”
- Piwen Wang · Charles R. Drew University Of Med & Sci$746,083
- Anup Kumer Kundu · Xavier University Of Louisiana$448,500
- Catherine Sarah Schrankel · University Of California, San Diego$238,349
- Joseph Terrell Smith · State University Of New York At Buffalo$205,606
- Eric Kwun Kwong · Virginia Commonwealth University$170,296
- Eli Grunblatt · University Of Washington$112,094
Research focus
Abcc1 GeneAbcg2 GeneAgedAkt Signaling PathwayAmerican Cancer SocietyAntineoplastic AgentsBcl2 GeneBehavior InfluenceBoneBrainBreast Cancer CellCancer CellCareerCause Of DeathCell FractionCell PhysiologyCell ProliferationCellsChildhood OsteosarcomaCisplatinCollaborationsComparativeCuesAbcb1 Gene
Grant awards (5)
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma$119,713
K01 · FY2025 · OD · contact PI
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma$119,713
K01 · FY2024 · OD · contact PI
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma$119,713
K01 · FY2023 · OD · contact PI
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma$119,713
K01 · FY2022 · OD · contact PI
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma$119,713
K01 · FY2021 · OD · contact PI